Literature DB >> 16953656

Escitalopram: a review of its use in the management of anxiety disorders.

Sohita Dhillon1, Lesley J Scott, Greg L Plosker.   

Abstract

Escitalopram (Cipralex, Lexapro, Seroplex, Sipralexa), the therapeutically active S-enantiomer of racemic citalopram (RS-citalopram), is a potent and highly selective serotonin reuptake inhibitor. It is effective and generally well tolerated in the treatment of moderate to severe generalised anxiety disorder (GAD) or social anxiety disorder (SAD), panic disorder (with or without agoraphobia) as well as obsessive-compulsive disorder (OCD). Moreover, escitalopram is at least as effective as paroxetine for the treatment of GAD, SAD or OCD and appears to achieve a more rapid response than racemic citalopram in the management of panic disorder. Generally, it has a more favourable tolerability profile than paroxetine in terms of fewer discontinuation symptoms. In addition, a favourable pharmacokinetic profile permits once-daily administration of the drug. Additional comparative studies are required to definitively position escitalopram with respect to other SSRIs and venlafaxine. Nevertheless, available clinical data indicate that escitalopram is an effective first-line treatment option for the management of GAD, SAD, panic disorder and OCD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953656     DOI: 10.2165/00023210-200620090-00010

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  63 in total

1.  The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects.

Authors:  B Søgaard; H Mengel; N Rao; F Larsen
Journal:  J Clin Pharmacol       Date:  2005-12       Impact factor: 3.126

2.  Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study.

Authors:  Siegfried Kasper; Dan J Stein; Henrik Loft; Rico Nil
Journal:  Br J Psychiatry       Date:  2005-03       Impact factor: 9.319

3.  An open trial of adjunctive escitalopram in bipolar depression.

Authors:  Manoela Fonseca; Jair C Soares; John P Hatch; Aida P Santin; Flavio Kapczinski
Journal:  J Clin Psychiatry       Date:  2006-01       Impact factor: 4.384

Review 4.  Escitalopram: a review of its use in the management of major depressive disorder.

Authors:  David Murdoch; Susan J Keam
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram.

Authors:  J D K Uys; C J F Muller; L Marais; B H Harvey; D J Stein; W M U Daniels
Journal:  Neuroscience       Date:  2005-11-28       Impact factor: 3.590

6.  Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.

Authors:  C Sánchez; P B F Bergqvist; L T Brennum; S Gupta; S Hogg; A Larsen; O Wiborg
Journal:  Psychopharmacology (Berl)       Date:  2003-04-26       Impact factor: 4.530

7.  Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.

Authors:  Jonathan R T Davidson; Anjana Bose; Andrew Korotzer; Hongjie Zheng
Journal:  Depress Anxiety       Date:  2004       Impact factor: 6.505

8.  Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys.

Authors:  Koen Demyttenaere; Ronny Bruffaerts; Jose Posada-Villa; Isabelle Gasquet; Viviane Kovess; Jean Pierre Lepine; Matthias C Angermeyer; Sebastian Bernert; Giovanni de Girolamo; Pierluigi Morosini; Gabriella Polidori; Takehiko Kikkawa; Norito Kawakami; Yutaka Ono; Tadashi Takeshima; Hidenori Uda; Elie G Karam; John A Fayyad; Aimee N Karam; Zeina N Mneimneh; Maria Elena Medina-Mora; Guilherme Borges; Carmen Lara; Ron de Graaf; Johan Ormel; Oye Gureje; Yucun Shen; Yueqin Huang; Mingyuan Zhang; Jordi Alonso; Josep Maria Haro; Gemma Vilagut; Evelyn J Bromet; Semyon Gluzman; Charles Webb; Ronald C Kessler; Kathleen R Merikangas; James C Anthony; Michael R Von Korff; Philip S Wang; Traolach S Brugha; Sergio Aguilar-Gaxiola; Sing Lee; Steven Heeringa; Beth-Ellen Pennell; Alan M Zaslavsky; T Bedirhan Ustun; Somnath Chatterji
Journal:  JAMA       Date:  2004-06-02       Impact factor: 56.272

9.  SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study.

Authors:  Gordon Parker; Lucy Tully; Amanda Olley; Dusan Hadzi-Pavlovic
Journal:  J Affect Disord       Date:  2006-03-03       Impact factor: 4.839

Review 10.  Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment.

Authors:  Kenneth Belzer; Franklin R Schneier
Journal:  J Psychiatr Pract       Date:  2004-09       Impact factor: 1.325

View more
  13 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Escitalopram in obsessive-compulsive disorder: a case series.

Authors:  Amit Zutshi; Suresh Bada Math; Y C Janardhan Reddy
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 3.  Escitalopram: a review of its use in the management of major depressive disorder in adults.

Authors:  Karly P Garnock-Jones; Paul L McCormack
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

4.  Ru-Catalyzed Asymmetric Addition of Arylboronic Acids to Aliphatic Aldehydes via P-Chiral Monophosphorous Ligands.

Authors:  Rui Miao; Yanping Xia; Yifei Wei; Lu Ouyang; Renshi Luo
Journal:  Molecules       Date:  2022-06-17       Impact factor: 4.927

5.  Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.

Authors:  Yuyan Jin; Bruce G Pollock; Ellen Frank; Giovanni B Cassano; Paola Rucci; Daniel J Müller; James L Kennedy; Rocco Nicola Forgione; Margaret Kirshner; Gail Kepple; Andrea Fagiolini; David J Kupfer; Robert R Bies
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

6.  Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.

Authors:  Naomi M Simon; Michael W Otto; John J Worthington; Elizabeth A Hoge; Elizabeth H Thompson; Richard T Lebeau; Samantha J Moshier; Alyson K Zalta; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2009-10-06       Impact factor: 4.384

Review 7.  Current management of tuberous sclerosis complex.

Authors:  Darcy A Krueger; David N Franz
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Effects of reboxetine and citalopram on appraisal of infant facial expressions and attentional biases.

Authors:  Alan Stein; Susannah Murphy; Adriane Arteche; Annukka Lehtonen; Allison Harvey; Michelle G Craske; Catherine Harmer
Journal:  J Psychopharmacol       Date:  2011-09-23       Impact factor: 4.153

9.  Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.

Authors:  Eiji Kirino
Journal:  Patient Prefer Adherence       Date:  2012-12-04       Impact factor: 2.711

10.  Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder.

Authors:  C François; S A Montgomery; N Despiegel; S Aballéa; J Roïz; P Auquier
Journal:  Int J Clin Pract       Date:  2008-08-28       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.